Brokerages Set Rhoen Klinikum AG (RHK) Target Price at $21.43

Rhoen Klinikum AG (ETR:RHK) has been given an average rating of “Sell” by the seven ratings firms that are covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is €21.43 ($24.92).

Several analysts have issued reports on RHK shares. Kepler Capital Markets set a €19.00 ($22.09) price target on shares of Rhoen Klinikum and gave the stock a “sell” rating in a research report on Wednesday, January 9th. Commerzbank set a €25.00 ($29.07) price objective on shares of Rhoen Klinikum and gave the company a “neutral” rating in a research report on Friday, November 9th. Independent Research set a €24.00 ($27.91) price objective on shares of Rhoen Klinikum and gave the company a “neutral” rating in a research report on Tuesday, November 13th. Cfra set a €22.00 ($25.58) price objective on shares of Rhoen Klinikum and gave the company a “sell” rating in a research report on Monday, November 12th. Finally, Warburg Research set a €25.20 ($29.30) price objective on shares of Rhoen Klinikum and gave the company a “neutral” rating in a research report on Friday, November 9th.

RHK traded up €0.02 ($0.02) during trading hours on Monday, hitting €23.00 ($26.74). 15,492 shares of the company’s stock were exchanged, compared to its average volume of 43,281. Rhoen Klinikum has a 1-year low of €25.08 ($29.16) and a 1-year high of €32.12 ($37.35).

About Rhoen Klinikum

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurological disorders, oncology, pneumology, orthopedic, accident, and surgeries; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.

Featured Story: Why do company’s buyback their stock?

Analyst Recommendations for Rhoen Klinikum (ETR:RHK)

Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply